Zejula

Discontinue if myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) is confirmed. Monitor CBCs weekly for the first month, monthly for the next 11 months, and periodically thereafter. Do not start therapy until recovery from hematological toxicity due to previous chemotherapy (Grade ≤1); discontinue if toxicities unresolved within 28 days after interruption (see full labeling). Monitor BP and HR at least weekly for the first 2 months, then monthly for the first year then periodically thereafter. Cardiovascular disorders (eg, coronary insufficiency, arrhythmias, hypertension); monitor closely. Discontinue promptly if posterior reversible encephalopathy syndrome (PRES) is suspected. Asthma. Aspirin sensitivity. Severe renal impairment or ESRD undergoing hemodialysis. Severe hepatic impairment (total bilirubin >3×ULN and any AST level). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during therapy and for ≥6 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 month after the last dose).